Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. Fu KK, et al. Among authors: jones cu. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16. doi: 10.1016/s0360-3016(00)00663-5. Int J Radiat Oncol Biol Phys. 2000. PMID: 10924966 Clinical Trial.
Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04.
Owen JB, Grigsby PW, Caldwell TM, Konski AA, Johnson DJ, Demas WF, Movsas B, Jones CU, Wasserman TH. Owen JB, et al. Among authors: jones cu. Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):633-9. doi: 10.1016/s0360-3016(00)00770-7. Int J Radiat Oncol Biol Phys. 2001. PMID: 11172943
Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial.
Yasar B, Suh YE, Chapman E, Nicholls L, Henderson D, Jones C, Morrison K, Wells E, Henderson J, Meehan C, Sohaib A, Taylor H, Tree A, van As N. Yasar B, et al. Int J Radiat Oncol Biol Phys. 2024 Sep 1;120(1):49-58. doi: 10.1016/j.ijrobp.2024.03.009. Epub 2024 Mar 16. Int J Radiat Oncol Biol Phys. 2024. PMID: 38499253 Free article. Clinical Trial.
Long term feeding tube use in head and neck cancer survivors - a secondary analysis of patient and treatment related factors.
Galloway TJ, Pugh SL, Ridge JA, Nguyen-Tan PF, Rosenthal DI, Gillison M, Garden AS, Dunlap N, Caudell JJ, Jones CU, Bauman JR, Bahig H, Shenouda G, Currey A, Koyfman SA, Stokes WA, Read N, Lyness JA, Yom SS, Le QT. Galloway TJ, et al. Among authors: jones cu. Int J Radiat Oncol Biol Phys. 2025 Jun 3:S0360-3016(25)00527-9. doi: 10.1016/j.ijrobp.2025.05.064. Online ahead of print. Int J Radiat Oncol Biol Phys. 2025. PMID: 40473230
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Machtay M, Torres-Saavedra PA, Thorstad W, Nguyen-Tân PF, Siu LL, Holsinger FC, El-Naggar A, Chung C, Cmelak A, Burtness B, Bednarz G, Quon H, Breen SL, Gwede CK, Dicker AP, Yao M, Jordan RC, Dorth J, Lee N, Chan JW, Dunlap N, Bar-Ad V, Stokes WA, Chakravarti A, Sher D, Rao S, Harris J, Yom SS, Le QT; NRG Oncology RTOG 0920 Collaborating Team. Machtay M, et al. J Clin Oncol. 2025 Apr 20;43(12):1474-1487. doi: 10.1200/JCO-24-01829. Epub 2025 Jan 22. J Clin Oncol. 2025. PMID: 39841939 Clinical Trial.
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.
Guan L, Torres-Saavedra PA, Zhao X, Major MB, Holmes BJ, Nguyen NK, Kumaravelu P, Hodge T, Diehn M, Zevallos J, Holsinger FC, Emami B, Jordan RC, Hayward MC, Sagar SM, Morrison W, Schultz C, Caudell JJ, Jones CU, Bratman SV, Galloway TJ, Ma DJ, Yom SS, Kudrimoti M, Kim HE, Harris J, Le QT, Hayes DN. Guan L, et al. Among authors: jones cu. Clin Cancer Res. 2025 May 1;31(9):1615-1624. doi: 10.1158/1078-0432.CCR-24-2334. Clin Cancer Res. 2025. PMID: 39656603 Clinical Trial.
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163].
Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin M, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Neil Reaume M, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA. Sartor O, et al. Among authors: jones cu. Eur Urol. 2024 Sep;86(3):289-290. doi: 10.1016/j.eururo.2024.06.009. Epub 2024 Jun 18. Eur Urol. 2024. PMID: 38897867 Free article.
Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis.
Gharzai LA, Morris E, Suresh K, Nguyen-Tân PF, Rosenthal DI, Gillison ML, Harari PM, Garden AS, Koyfman S, Caudell JJ, Jones CU, Mitchell DL, Krempl G, Ridge JA, Gensheimer MF, Bonner JA, Filion E, Dunlap NE, Stokes WA, Le QT, Torres-Saavedra P, Mierzwa M, Schipper MJ. Gharzai LA, et al. Among authors: jones cu. Lancet Oncol. 2024 Mar;25(3):366-375. doi: 10.1016/S1470-2045(24)00016-0. Lancet Oncol. 2024. PMID: 38423050 Free PMC article.
62 results